Skip to content
Peptide Atlas
All peptides

Gonadorelin

Tier 2 · Preclinical
Also known as GnRH · LHRH · Factrel · Lutrelef

Gonadorelin has Tier 1 human clinical evidence: it is used as an approved diagnostic agent for pituitary gonadotrope testing (src-1) and pulsatile formulations (Lutrepulse) were indicated for ovulation induction in hypothalamic amenorrhea (src-2, src-3). Fertility and CHH efficacy figures come from retrospective observational cohorts and meta-analyses (Tier 2, src-7/8/9), while anticancer effects are largely preclinical/in-vitro (Tier 2). The popular TRT-adjunct use rests only on expert opinion and single-vendor anecdotal reports (Tier 3, src-12). Regulatory/market availability is contested across sources.

Half-life
~0.5 h
Routes
Subcutaneous injection · Intravenous injection · Nasal spray · Pulsatile subcutaneous/IV infusion pump
Goals
Fertility and reproductive function · Diagnostic pituitary/HPG axis evaluation · Hormone optimization (off-label TRT adjunct) · Libido (anecdotal)
Cost / mg
Not recorded

How it works

Gonadorelin is a lab-made copy of the body's own gonadotropin-releasing hormone (GnRH), the master hormone from the hypothalamus that tells the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These in turn drive the testes and ovaries to make sex hormones and support sperm and egg development. A crucial feature is timing: the natural hormone is released in pulses every 90-120 minutes, and delivering gonadorelin in matching pulses keeps the pituitary responsive. If instead it is given continuously, the pituitary receptors shut down and hormone output paradoxically falls. Because of this, it is used both as a single-dose diagnostic test of pituitary function and, via a programmable pump giving pulses, to induce ovulation or restore fertility in people whose own hypothalamus is not producing GnRH.

Overview

Overview

Gonadorelin (also known as GnRH, LHRH, and by the brand names Factrel and Lutrelef/Lutrepulse) is a synthetic decapeptide with an amino acid sequence identical to endogenous gonadotropin-releasing hormone. Its structure is pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (molecular formula C55H75N17O13, ~1182 g/mol, CAS 33515-09-2), manufactured by solid-phase peptide synthesis. The native hormone's structure was independently elucidated in 1971 by Andrew Schally's and Roger Guillemin's groups, work recognized by the 1977 Nobel Prize, and gonadorelin was available medically as Factrel by 1978.

Physiological Role

GnRH is the master central regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Released from the hypothalamus, it acts on GnRH type I receptors on anterior-pituitary gonadotrophs to stimulate secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH acts on testicular Leydig cells and ovarian theca cells; FSH supports Sertoli-cell function, spermatogenesis, and ovarian follicle development. Together they govern reproductive development in children and fertility in adults.

A defining feature is pulsatility: natural GnRH is secreted in pulses roughly every 90-120 minutes. Pulsatile delivery sustains receptor sensitivity and maintains gonadotropin output, whereas continuous, non-pulsatile stimulation downregulates receptors and paradoxically suppresses LH and FSH. This was demonstrated in rhesus monkeys, where continuous infusion suppressed gonadotropins while hourly pulses (1 mcg/min for 6 min every hour) fully restored LH/FSH in animals with hypothalamic lesions. Gonadorelin is the native sequence, distinct from longer-acting D-amino-acid-substituted agonists (leuprolide, triptorelin, nafarelin) that are used for sex-hormone suppression.

Diagnostic Use

Gonadorelin is used as a diagnostic agent (the GnRH stimulation test) to evaluate the functional capacity of anterior-pituitary gonadotropes and assess the HPG axis. The LH response tests for suspected gonadotropin deficiency and evaluates residual gonadotropic function after pituitary tumor removal, surgery, or irradiation. A normal response indicates functional pituitary gonadotropes. In normal adult males mean peak LH is ~60 mIU/mL at ~34 minutes; in women during the early follicular phase, ~68 mIU/mL at ~72 minutes. The single-injection test does not identify the pathophysiological cause of a subnormal response and does not measure pituitary gonadotropic reserve.

Therapeutic Use

Delivered in pulses via a programmable ambulatory infusion pump, gonadorelin (Lutrepulse/Lutrelef, gonadorelin acetate) is indicated for induction of ovulation in women with primary hypothalamic amenorrhea, and is used for hypogonadotropic hypogonadism (e.g., Kallmann syndrome), delayed puberty, cryptorchidism, and infertility. A 25-year retrospective cohort (66 patients, 212 cycles, 10 mcg/90-min pulse) reported a 96% per-cycle ovulation rate, 74.4% clinical pregnancy per treatment episode, 65.9% live birth, 75% monofollicular ovulation, and only 1.6% multiple pregnancy with no severe adverse events. In men with congenital hypogonadotropic hypogonadism (CHH), pulsatile therapy produced earlier onset of spermatogenesis (5.3 months sooner) and greater testicular volume gains than combination gonadotropin therapy in meta-analysis; a series of 54 CHH men saw testosterone rise from 48 to 381 ng/dL and spermatogenesis in 79.4% at a mean of 6.5 months. These fertility/CHH figures come from retrospective observational studies and meta-analyses, not randomized controlled trials.

Off-Label TRT Adjunct

Gonadorelin is promoted off-label as a testosterone-replacement-therapy adjunct to preserve testicular volume, intratesticular testosterone, and spermatogenesis and to prevent HPG-axis suppression during exogenous testosterone use. This use lacks published RCT support and rests on expert opinion and anecdotal clinical reports. A single vendor community report (25 users) noted 97% positive reports with libido most frequently cited (181 reports) — a single-source, anecdotal signal.

Broader GnRH Pharmacology and Oncology

GnRH agonists (D-amino-acid-substituted) produce efficient inhibition of gonadotropins and sex steroids and are used for pharmacological castration in hormone-dependent cancers (prostate, breast), as well as uterine fibroids, precocious puberty, endometriosis, and assisted reproduction; GnRH antagonists (e.g., Cetrorelix) suppress gonadotropins immediately without the initial flare. GnRH and its receptor are overexpressed in ovarian, endometrial, breast, and prostate tumors, and preclinical/in-vitro work suggests antiproliferative effects via non-classical signaling — though the cytotoxic conjugate Zoptarelin Doxorubicin was not superior to free doxorubicin in a phase III endometrial cancer trial, and these anticancer effects remain largely preclinical.

Regulatory Note

Sources disagree on current availability: gonadorelin has been described as FDA-approved as a diagnostic (Factrel) with Lutrepulse approved then discontinued; other sources indicate the current label is veterinary-only or that, as of 2026, no FDA-approved gonadorelin product is marketed in the U.S. with only compounded material available.

What the research shows

236 findings extracted from the 28 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 3 human trial findings, 29 human study findings, 7 animal findings, 3 in vitro findings, 8 expert opinion findings, 1 anecdotal finding and 1 theoretical finding.

  • human trialIn cases where there is a normal response, it indicates the presence of functional pituitary gonadotropes1

  • human trialThe cytotoxic GnRH-analog Zoptarelin Doxorubicin has shown encouraging activity in a phase II trial in patients with advanced or recurrent EC, which expressed GnRH-R5

  • human trialIn a phase III trial in patients with EC of unknown GnRH-R expression, the cytotoxic GnRH doxorubicin conjugate was not superior to free doxorubicin5

  • human studyGonadorelin, used as a test, has been studied only in children 12 years of age and older2

  • human studyIn ovarian cancer, GnRH is involved in the regulation of proliferation and metastasis4

  • human studyMost endometrial cancer express GnRH and its receptor (GnRH-R) as part of an autocrine system regulating proliferation, the cell cycle, and apoptosis5

  • human studyTreatment with conventional doses of GnRH-agonists that suppress pituitary gonadotropin secretion and ovarian estrogen production has become part of fertility preserving therapy of early EC or its pre-cancer (atypical endometrial hyperplasia)5

  • human studyConventional doses of GnRH-agonists had marginal activity in advanced or recurrent EC5

Show the remaining 44

  • human studyGnRH analogues use in cancer therapy result in pharmacological castration (i.e. ovariectomy and orchiectomy), providing an androgen and estrogen ablation7

  • human studyGnRH exert an inhibitory action on the growth of hormone-dependent human and canine mammary tumor7

  • human studyGnRH antagonist causes suppression of gonadotrophin secretion immediately after administration8

  • human studyA single subcutaneous administration of 3 or 5 mg of Cetrorelix in the late follicular stage was sufficient to prevent the LH surge for 6-17 days8

  • human studyGnRH agonist treatment induces low LH, whereas flushes remain, even when oestrogens are supplemented9

  • human studyHigh doses of oestradiol during GnRH agonist treatment do not abolish flushes9

  • human studyAlpha 2-adrenergic agonists such as clonidine and alpha-methyldopa abolish flushes during treatment with GnRH agonists9

  • human studyLHRH receptor expression detected in hepatocellular carcinoma (HCC) tumor cells with 82.61% positive rate vs 15% in normal tissue17

  • human studyLHRH receptor expression in breast cancer tumor cells with 95% positive rate vs 20% in normal tissue17

  • human studyLHRH receptor expression in prostate cancer tumor cells with 70% positive rate vs 40% in normal tissue17

  • human studyLHRH receptor expression in lung cancer tumor cells with 85% positive rate vs 15.79% in normal tissue17

  • human studyLHRH receptor expression in endometrial cancer tumor cells with 80% positive rate vs 16.67% in normal tissue17

  • human studyA 2020 meta-analysis pooling 420 men across eight comparative studies confirmed pulsatile GnRH achieves earlier spermatogenesis onset versus combined gonadotropin therapy in congenital hypogonadotropic hypogonadism24

  • human studyPulsatile gonadorelin effectively stimulates LH and FSH in men with congenital hypogonadotropic hypogonadism24

  • human studyPulsatile GnRH therapy has been studied in congenital hypogonadotropic hypogonadism (CHH)25

  • human studyA 2021 systematic review and meta-analysis compared pulsatile GnRH therapy with gonadotropin therapy for spermatogenesis in male CHH25

  • human studyA 2025 retrospective study evaluated pulsatile GnRH pump therapy in adult male CHH patients25

  • human studyPulsatile GnRH has been studied as a way to induce ovulation in hypothalamic amenorrhea when the central pulse generator is suppressed25

  • human studyIn a 25-year retrospective cohort using 10 µg per 90-minute subcutaneous pulse, per-cycle ovulation rate was 96%, clinical pregnancy rate was 74.4% per treatment episode, and live birth rate was 65.9%26

  • human studyIn the cohort of 66 patients with 82 treatment episodes and 212 ovulation induction cycles, monofollicular ovulation occurred in 75% of cycles, multiple pregnancy rate was 1.6%, and no severe adverse events were reported26

  • human studyA meta-analysis of 7 studies with 420 male patients showed pulsatile GnRH produced earlier onset of spermatogenesis (5.3 months sooner; p=0.004) and greater testicular volume increases (p=0.01) compared to combination gonadotropin therapy26

  • human studyIn a retrospective series of 54 adult males with CHH using 10 µg/90-min pulses, serum testosterone rose from 48 to 381 ng/dL over two years, testicular volume from 3.19 to 9.73 mL, and spermatogenesis was achieved in 79.4% of evaluable patients at a mean of 6.5 months26

  • human studyIn normal adult males during GnRH stimulation test, mean peak LH is approximately 60 mIU/mL at around 34 minutes26

  • human studyIn women during the early follicular phase (days 1-7) during GnRH stimulation test, mean peak LH is approximately 68 mIU/mL at around 72 minutes26

  • animalIn rhesus monkeys with hypothalamic lesions, pulsatile GnRH (1 microgram/min for 6 minutes every hour) fully restored and maintained LH and FSH secretion13

  • animalGnRH and NGnRH treatments significantly decreased the duration of estrus compared with the control16

  • animalBoth GnRH and NGnRH increased the number of corpora lutea compared with the control at day 10 after mating16

  • animalTreatment with GnRH increased serum estradiol concentrations from day 7 to 42 after mating compared with NGnRH and control treatments16

  • animalThe highest serum progesterone concentration was observed in the GnRH group, followed by the NGnRH and control groups16

  • animalBoth gonadorelin treatments significantly increased the twinning rate, the number of embryos at days 28 and 42, and prolificacy and decreased pregnancy losses compared with the control16

  • animalGnRH resulted in a higher progesterone-to-estradiol ratio compared with the control, followed by NGnRH16

  • in vitroThe proliferation of human ovarian cancer cell lines is time- and dose-dependently reduced by GnRH and its superagonistic analogs20

  • in vitroThe proliferation of ovarian cancer cells is dose- and time-dependently reduced by GnRH-II in a greater extent than by GnRH-I superagonists20

  • in vitroGnRH-I antagonist Cetrorelix has comparable antiproliferative effects as GnRH-I agonists in ovarian cancer cell lines except for the EFO-27 cell line20

  • expert opinionThe single injection test does not determine the patho-physiological cause for the subnormal response and does not measure pituitary gonadotropic reserve1

  • expert opinionDiagnosis of hypothalamic amenorrhea or hypogonadism is based on the exclusion of other causes of the dysfunction, since there is currently no practical technique to directly assess hypothalamic function.6

  • expert opinionMaintains intratesticular testosterone and sperm production22

  • expert opinionGonadorelin is FDA approved for specific indications and widely studied for its potential in reproductive health and hormonal optimization23

  • expert opinionGonadorelin can stimulate ovulation in females with anovulation and enhance spermatogenesis in males with fertility challenges23

  • expert opinionGonadorelin can help prevent testicular atrophy in males undergoing testosterone replacement therapy by stimulating endogenous testosterone production23

  • expert opinionDirect evidence for gonadorelin use as a TRT adjunct remains limited as of April 202624

  • expert opinionThe majority (84%) of respondents did not prescribe hormonal therapy for undescended testes, predominantly due to a paucity of scientific evidence (76%)27

  • anecdotalMost reported benefit is libido (181 reports)22

  • theoreticalGnRH antagonists prevent the early hormonal flare, have a faster onset of action, and have a lower risk of cardiovascular problems compared to typical GnRH agonists10

How it works

Based on 15 human study findings, 14 animal findings, 12 in vitro findings, 29 expert opinion findings and 28 theoretical findings.

  • human studyThe hypothalamus-pituitary-gonadal (HPG) axis is the endocrine regulation system that controls the woman's cycle4

  • human studyThe gonadotropin-releasing hormone (GnRH) plays the central role in the HPG axis4

  • human studyGnRH receptors are expressed in the pituitary gonadotrophic cells4

  • human studyGnRH receptors are expressed in reproductive organs such as the ovary4

  • human studyGnRH receptors are expressed in tumors originating from the ovary4

  • human studyGnRH acts indirectly via the HPG axis in ovarian tumors4

  • human studyGnRH acts directly via GnRH receptors on the surface of ovarian cancer cells4

  • human studyGnRH analogues produce an efficient inhibition of gonadotropins and sex steroid hormones7

Show the remaining 90

  • human studyGnRH antagonist binds competitively to receptors and prevents endogenous GnRH from exerting its stimulatory effect on pituitary cells8

  • human studyA nadir of LH precedes the onset of the flush and a flush is never seen without an LH pulse9

  • human studyAfter surgical and medical (GnRH agonist) hypophysectomy flushing occurs while LH is absent, thus LH itself is not the cause of the flush9

  • human studyFlushes are preceded by a spike of LH-RH, suggesting GnRH involvement9

  • human studyPulsatile administration of GnRH does not induce flushes, whereas continuous administration does9

  • human studyInterference with the pulsatile pattern of GnRH causes flushes9

  • human studyDysregulation of the GnRH releasing clock center in the nucleus arcuatus in the mediobasal hypothalamus is associated with altered central alpha-receptor activity which results in lowering of the set point of the central thermostat and the circulatory changes9

  • animalThe structure of GnRH was independently elucidated in 1971 by Andrew Schally's group from porcine hypothalami and confirmed by Roger Guillemin's laboratory from ovine hypothalami13

  • animalIn rhesus monkeys, continuous GnRH infusion paradoxically suppressed LH and FSH, while intermittent hourly pulses maintained normal gonadotropin output13

  • animalContinuous GnRH infusion causes sustained receptor occupancy leading to GnRH-R internalization and receptor mRNA downregulation to ~35-50% of control levels by 2-4 weeks13

  • animalGnRH regulates the secretion of both FSH and LH14

  • animalGnRH is dispensable for FSH function in non-mammalian vertebrates14

  • animalCholecystokinin functions as FSH-releasing hormone (FSH-RH)14

  • animalHypothalamic cholecystokinin-expressing neurons directly affect FSH cells through the cholecystokinin receptor Cck2rb14

  • animalCholecystokinin increases the expression and release of FSH14

  • animalKnockout of the cholecystokinin-FSH pathway minimizes FSH expression and results in failure of folliculogenesis14

  • animalReproduction-related immunoinfertility involves immunization against antigens related to reproductive hormones including LHRH, GnRH, Gonadal steroids, PGF2α and oxytocin15

  • animalAnovulation, delayed ovulation, sperm immobilization, failure of fertilization, prolonged uterine involution, extended calving interval, prolonged post-partum estrus and reduced conception rate could result from immunoinfertility due to blockage of receptor sites by antibodies formed against hormones15

  • animalChitosan-TPP nanoparticles showed 91.2% entrapment efficiency for GnRH16

  • animalI-LHRH labeled peptide retained high receptor binding ability and biological activity17

  • animalContinuous infusion of GnRH causes pituitary desensitization and suppression of LH and FSH due to GnRH receptor downregulation24

  • in vitroGnRH-I and GnRH-II agonists, and antagonists as well as cytotoxic GnRH-I analogs, have been shown to inhibit proliferation and to induce apoptosis in human EC cell lines in pre-clinical models5

  • in vitroGonadorelin displays UV-Vis optical absorbance peak at 280 nm associated with the presence of a tyrosine and a tryptophan in its sequence12

  • in vitroTc-LHRH demonstrated saturable receptor binding characteristics with high affinity (RT = 23.2174 pmol, KD = 0.4348 nmol)17

  • in vitroThe expression of GnRH (GnRH-I, LHRH) and its receptor has been demonstrated as part of an autocrine regulatory system of cell proliferation in human malignant tumors, including cancers of the ovary20

  • in vitroThe classical GnRH receptor signal-transduction mechanisms known to operate in the pituitary are not involved in the mediation of antiproliferative effects of GnRH analogs in cancer cells20

  • in vitroThe GnRH receptor interacts with the mitogenic signal transduction of growth-factor receptors via activation of a phosphotyrosine phosphatase resulting in downregulation of cancer cell proliferation20

  • in vitroGnRH activates nucleus factor kappaB (NFkappaB) and protects cancer cells from apoptosis20

  • in vitroGnRH induces activation of the c-Jun N-terminal kinase/activator protein-1 (JNK/AP-1) pathway independent of PKC or MAPK/ERK20

  • in vitroHuman ovarian cancer cells express a putative second GnRH receptor specific for GnRH type II (GnRH-II)20

  • in vitroAfter GnRH-I receptor knock down, the antiproliferative effects of GnRH-I agonist Triptorelin were abrogated while the effects of GnRH-I antagonist Cetrorelix and GnRH-II were still existing20

  • in vitroIn the ovarian cancer cell line EFO-27, GnRH-I receptor but not putative GnRH-II receptor expression was found20

  • in vitroThe antiproliferative effects of GnRH-I antagonist Cetrorelix and GnRH-II are not mediated through the GnRH-I receptor in ovarian cancer cells20

  • expert opinionGonadorelin is a medicine that is the same as gonadotropin-releasing hormone (GnRH) that is naturally released from the hypothalamus gland2

  • expert opinionGnRH causes the pituitary gland to release other hormones (luteinizing hormone [LH] and follicle-stimulating hormone [FSH])2

  • expert opinionLH and FSH control development in children and fertility in adults2

  • expert opinionThe medication is a form of the endogenous GnRH and is identical to it in chemical structure3

  • expert opinionGonadotropin releasing hormone (GnRH) is a decapeptide first described to be secreted by the hypothalamus to regulate pituitary gonadotropin secretion5

  • expert opinionLUTREPULSE is intended to initiate events including the production of reproductive hormones (e.g., estrogens and progesterone).6

  • expert opinionGnRH analogues are synthetic compounds derived from decapeptide neurohormones (LHRH; LH/FSH-RH)7

  • expert opinionGnRH receptors have a role in cancer and their connection with steroid hormones7

  • expert opinionA tight link exists between steroid hormones and GnRH analogues both on central pituitary gonadal axis and on tumor receptors peripherically7

  • expert opinionGnRH agonists are derived from the native molecule by substitution of a D-amino acid in position 6 which increases their resistance to enzymatic breakdown and their affinity for LH-RH receptors18

  • expert opinionGnRH agonists strongly reduce LH secretion, by preventing the production of the LH-beta subunit18

  • expert opinionThe production of LH-alpha subunit is markedly increased and remains responsive to exogenous GnRH injection18

  • expert opinionGnRH agonists offer sustained efficacy even after one or two days of withdrawal18

  • expert opinionGnRH agonists induce initial hyperstimulation of the gonadotrophs, the so-called flare up, characteristic of the superagonistic effect18

  • expert opinionGonadorelin (GnRH, gonadotropin releasing hormone) is a neuropeptide that stimulates the secretion of gonadotropins21

  • expert opinionGonadorelin is synthesized as part of a large prohormone21

  • expert opinionGonadorelin is a synthetic analog of gonadotropin releasing hormone (GnRH) which is naturally produced in the hypothalamus23

  • expert opinionGnRH plays a critical role in regulating the release of two key reproductive hormones lutenizing hormone (LH) and follicle stimulating hormone (FSH)23

  • expert opinionGonadorelin acts on the pituitary gland to stimulate the release of lutenizing hormone and follicle stimulating hormone23

  • expert opinionContinuous administration of gonadorelin can suppress LH and FSH secretion due to downregulation of GnRH receptors in the pituitary gland23

  • expert opinionGonadorelin is a synthetic decapeptide identical to endogenous GnRH that stimulates pituitary LH and FSH release when delivered in pulsatile pulses24

  • expert opinionGnRH is a ten-amino-acid peptide produced by specialized neurons in the hypothalamus24

  • expert opinionGnRH is released in discrete pulses into the hypothalamic-pituitary portal circulation where it stimulates synthesis and release of LH and FSH24

  • expert opinionGonadorelin is synthetic gonadotropin-releasing hormone, a ten-amino-acid peptide that can stimulate the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH)25

  • expert opinionLH acts on Leydig cells in the testes and theca cells in the ovaries. FSH supports Sertoli-cell function, spermatogenesis and ovarian follicle development25

  • expert opinionPhysiologic GnRH is pulsatile. Continuous or poorly timed exposure can behave differently25

  • expert opinionPulsatile GnRH can stimulate the reproductive axis when the pituitary and gonads are capable of responding25

  • expert opinionContinuous GnRH agonist exposure can eventually downregulate the axis25

  • expert opinionGonadorelin is the native GnRH sequence in drug form, not the same as longer-acting GnRH agonists such as leuprolide, triptorelin or nafarelin25

  • theoreticalOverexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer10

  • theoreticalPeptidomimetic GnRH antagonists provide fast and reversible suppression of gonadotropins by directly blocking GnRH-R10

  • theoreticalGonadorelin is a ten-membered synthetic oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, glycyl, leucyl, arginyl, prolyl and glycinamide residues joined in sequence11

  • theoreticalIt has a role as a gonadotropin releasing hormone agonist11

  • theoreticalGnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary11

  • theoreticalRecombinant Gonadorelin is a synthetic luteinizing hormone releasing hormone (LHRH) identical to or similar to the endogenous hormone11

  • theoreticalGonadorelin binds to transmembrane LHRH receptors on pituitary gonadotrophic cells, thereby stimulating synthesis and secretion of gonadotropins11

  • theoreticalContinuous administration of gonadorelin desensitizes the gonadotrophic cells, a negative feedback effect11

  • theoreticalGonadorelin is a bioactive synthetic decapeptide with molecular weight 1182.33 Da and chemical structure that coincides with the endogenous GnRH with a pyroglutamic acid at the N-terminus and an amidated C-terminal12

  • theoreticalThe amino acid residues -ProGly- at the C-terminus can undergo a beta-turn motif through hydrogen bonds, which can be relevant for the three-dimensional arrangement12

  • theoreticalGnRH is the pivotal central regulator of the hypothalamic-pituitary-gonadal (HPG) axis and plays a significant role in the processes of mammalian reproduction12

  • theoreticalThe pulsatile secretion of GnRH by neurons in the mediobasal hypothalamus stimulates the synthesis and release of pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), by binding to GnRH receptors (GnRH-R) mainly expressed in the anterior pituitary12

  • theoreticalGnRH-R overexpression takes place in gonadal steroid-dependent tumors, such as prostate, breast, endometrial tumors, and ovarian adenocarcinomas12

  • theoreticalGnRH is first synthesized and released by the hypothalamus as pre-prohormone, a large precursor protein named progonadoliberin-1 precursor (MW = 10,380 Da, length 92 aa)12

  • theoreticalGonadorelin is a decapeptide with the sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂13

  • theoreticalGnRH is the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis, controlling reproductive function in both sexes by stimulating the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH)13

  • theoreticalGonadorelin binds to the GnRH type I receptor (GnRH-R), a seven-transmembrane G protein-coupled receptor (GPCR) expressed on gonadotroph cells of the anterior pituitary13

  • theoreticalGnRH-R couples primarily to Gq/G11 proteins, activating phospholipase C-beta (PLCbeta) which generates inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG)13

  • theoreticalGonadorelin (GnRH/LHRH) is a decapeptide with structure pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH219

  • theoreticalGnRH acts upon 7-trans membrane spanning GnRH receptors in the pituitary19

  • theoreticalGnRH action leads to secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)19

  • theoreticalLH and FSH act on reproductive organs regulating gonadal steroid production, spermatogenesis and follicular development19

  • theoreticalGonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a 10-amino acid hypothalamic peptide22

  • theoreticalGnRH receptor (GnRHR) agonism at anterior pituitary gonadotrophs; pulsatile dosing stimulates LH and FSH release22

  • theoreticalGonadorelin is a synthetic decapeptide with an amino acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH)26

  • theoreticalGonadorelin binds to GnRH receptors on gonadotroph cells of the anterior pituitary, activating intracellular signaling that drives synthesis and release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH)26

  • theoreticalPulsatile delivery mimicking the physiological 90-to-120-minute intermittent secretory rhythm sustains receptor sensitivity and maintains gonadotropin output26

  • theoreticalContinuous, non-pulsatile stimulation downregulates GnRH receptors and paradoxically suppresses LH and FSH secretion26

Dosing

Based on 3 human trial findings, 1 animal finding and 8 expert opinion findings.

  • human trialAdults and Elderly: 100 micrograms, subcutaneously or intravenously1

  • human trialIn females for whom the phase of the menstrual cycle can be established, the test should be performed in the early follicular phase (days 1-7)1

  • human trialEach vial contains 100 micrograms of gonadorelin as gonadorelin hydrochloride1

  • animalThe nanoformulation allowed a 75% reduction in the conventional dose of gonadorelin without affecting the fertility and prolificacy of goats16

  • expert opinionIt is given by injection into a blood vessel or fat or as a nasal spray3

  • expert opinionThe usual dosage delivered is 5 to 20 μg of gonadorelin per pulse every 90 to 120 minutes3

  • expert opinionTypical dose 100 mcg 2–3× weekly subcutaneous for TRT adjunct protocol22

  • expert opinionTypical dosage is 100 mcg (as prescribed)26

Show the remaining 4

  • expert opinionFor pituitary function assessment (GnRH stimulation test), a single dose of 100 µg is administered intravenously or subcutaneously26

  • expert opinionFor ovulation induction in hypothalamic amenorrhea, 10 to 20 µg per pulse is delivered subcutaneously every 90 minutes via a programmable ambulatory infusion pump26

  • expert opinionThere was no clear preference in administration type for hormonal therapy in undescended testes (50% intramuscular injection, 50% nasal spray)27

  • expert opinionNo standardized schedule was used for hormonal therapy in undescended testes27

How the body handles it

Based on 1 human trial finding, 3 animal findings, 2 in vitro findings, 6 expert opinion findings and 2 theoretical findings.

  • human trialAfter reconstitution with 1 ml of water for injections, the resulting solution contains 100 micrograms/ml of gonadorelin as gonadorelin hydrochloride1

  • animalIncrease in serum progesterone concentration started earlier on day 7 in the GnRH group but later on day 14 in the NGnRH group16

  • animalRadiolabeled LHRH showed rapid blood clearance within 72 hours in mice with major radioactive accumulation in liver and kidneys17

  • animalThe biological half life of D-TRP6-LHRH agonist injected by the subcutaneous route is 10 times greater than that observed after intravenous injection18

  • in vitroTc-LHRH radiochemical purity ranged from 93.9-96.4%17

  • in vitroTc-LHRH marking rate was 97.9-100.0%17

  • expert opinionMultiple doses of gonadorelin can result in increase of estrogens and progestins in women or androgens in men2

  • expert opinionGonadorelin is metabolized by hydrolysis into smaller peptide components3

Show the remaining 6

  • expert opinionGonadorelin has a distribution half-life of 2 to 10 minutes and a very short terminal half-life of 10 to 40 minutes3

  • expert opinionPeptidic agonists and antagonists of GnRH receptor are limited to predominantly parenteral administration due to poor oral bioavailability19

  • expert opinionReconstituted solution should be refrigerated (2–8°C) and used within 28 days22

  • expert opinionWhen administered as a single bolus dose gonadorelin causes a transient surge in LH and FSH23

  • theoreticalGonadorelin acetate is a formulation containing 50-mcg gonadorelin diacetate tetrahydrate per milliliter, which is equivalent to 43 mcg/mL of gonadorelin, used in aqueous solution12

  • theoreticalPlasma half-life is 2 to 10 minutes (distribution phase) and 10 to 40 minutes (terminal phase); the peptide is cleared primarily by enzymatic hydrolysis26

Safety and side effects

Based on 1 human trial finding, 5 human study findings, 11 expert opinion findings and 4 anecdotal findings.

  • human trialThe safety and efficacy of gonadorelin in children under one year have not been established1

  • human studyThe medicine has not caused different side effects or problems in children 12 years of age and older than it does in adults2

  • human studyChildren up to 12 years of age may not be sensitive to the effects of gonadorelin2

  • human studyThere have been few cases of hyperstimulation (<1%) with pulsatile GnRH therapy.6

  • human studyOvarian hyperstimulation syndrome (OHSS) is a known risk with ovulation induction therapies, but is rare with pulsatile GnRH therapy.6

  • human studyOvarian cancer has been reported in a very small number of infertile women who have been treated with fertility drugs, but a causal relationship with treatments of fertility drugs has not been established.6

  • expert opinionInfants may be very sensitive to the effects of gonadorelin and use in infants is not recommended2

  • expert opinionUse of gonadorelin when GnRH adenoma exists may cause problems in the pituitary gland and could result in sudden blindness2

Show the remaining 13

  • expert opinionLUTREPULSE is contraindicated in women with any condition that could be exacerbated by pregnancy, such as pituitary prolactinoma.6

  • expert opinionPatients who have ovarian cysts should not receive LUTREPULSE.6

  • expert opinionAny condition that may be worsened by reproductive hormones, such as a hormonally-dependent tumor, is a contraindication to the use of LUTREPULSE.6

  • expert opinionThe preservation of the endogenous feedback mechanisms makes severe hyperstimulation (with ascites and pleural effusion) rare with pulsatile GnRH therapy.6

  • expert opinionMultiple pregnancies are a possibility that can be minimized by careful attention to the recommended doses and ultrasonographic monitoring of the ovarian response to therapy.6

  • expert opinionGnRH is a natural substance normally present in humans, so long-term studies in animals have not been performed to evaluate carcinogenic potential.6

  • expert opinionPotential for allergic reaction — discontinue if rash or hives occur22

  • expert opinionNo FDA-approved gonadorelin product is currently marketed in the United States as of April 202624

  • expert opinionCurrent DailyMed Factrel label is veterinary and marked for animal use only; FDA records also show historical human gonadorelin applications25

  • anecdotalInjection site reactions (redness, bruising, mild pain)22

  • anecdotalNausea reported by 2 users22

  • anecdotalInjection site irritation reported by 2 users22

  • anecdotalHeadache reported by 1 user22

What people use it for

Based on 5 human trial findings, 6 human study findings, 2 animal findings, 20 expert opinion findings and 3 theoretical findings.

  • human trialGonadorelin 100 micrograms powder for solution for injection is indicated for evaluating the functional capacity and response of the gonadotropes of the anterior pituitary1

  • human trialThe LH response is used in testing patients with suspected gonadotropin deficiency, whether due to the hypothalamus alone or in combination with anterior pituitary failure1

  • human trialGonadorelin injection is indicated for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumour or surgery and/or irradiation1

  • human trialThe gonadorelin test complements the clinical assessment of patients with a variety of endocrine disorders involving the hypothalamic-pituitary axis1

  • human trialLUTREPULSE (gonadorelin acetate) is indicated for the induction of ovulation in women with primary hypothalamic amenorrhea.6

  • human studyGonadorelin is used to test how well the hypothalamus and the pituitary glands are working2

  • human studyGonadorelin is used to cause ovulation (release of an egg from the ovary) in women who do not have regular ovulation and menstrual periods because the hypothalamus gland does not release enough GnRH2

  • human studyGnRH analogues have a key role in hormone dependent cancer, particularly breast and prostate cancer7

Show the remaining 28

  • human studyGnRH antagonist can be used to delay the LH surge in cases prone to OHSS (ovarian hyperstimulation syndrome)8

  • human studyGnRH antagonist can be administered during the luteal phase to decrease the activity of corpora lutea8

  • human studyGnRH antagonist can correct the LH/FSH ratio in polycystic ovarian disease with elevated LH8

  • animalImmunoinfertility in animals can be treated by giving sexual rest to females, using reproductive technologies such as fertilization, gamete intra fallopian tube transfer, and intracytoplasmic sperm injection, sperm washing, and treating animals with immunomodulators such as LPS and Oyster glycogen15

  • animalAdministration of GnRH at the time of estrus improved the prolificacy of goats by increasing both the ovulation rate and the number of embryos16

  • expert opinionGonadorelin is a gonadotropin-releasing hormone agonist (GnRH agonist) which is used in fertility medicine and to treat amenorrhea and hypogonadism3

  • expert opinionGonadorelin is used as a diagnostic agent to assess pituitary gland function3

  • expert opinionGonadorelin is also used in the treatment of primary hypothalamic amenorrhea, hypogonadotropic hypogonadism (e.g., Kallmann syndrome), delayed puberty, cryptorchidism, and infertility3

  • expert opinionUnlike other GnRH analogues, it is not used to suppress sex hormone production3

  • expert opinionTherapy with LUTREPULSE should be conducted by physicians familiar with pulsatile GnRH delivery and the clinical ramifications of ovulation induction.6

  • expert opinionShort-acting GnRH agonists were recommended for triggering ovulation in cases with high risk of developing OHSS8

  • expert opinionGonadorelin is FDA-approved as diagnostic (Factrel); Lutrepulse (pulsatile pump) was approved then discontinued13

  • expert opinionPeptidic GnRH agonists are therapeutically employed in treatment of prostate and breast tumours, uterine fibroids, precocious puberty, endometriosis, premenstrual syndrome, contraception and infertility19

  • expert opinionPeptidic GnRH antagonists have been employed commercially in treatment of infertility during assisted reproductive therapy19

  • expert opinionGonadorelin has been introduced into medical and veterinary practice for regulation of pituitary abnormalities and study of normal physiology21

  • expert opinionPrevents HCG-independent hypogonadism during TRT22

  • expert opinionWidely used in men on testosterone replacement therapy (TRT) to maintain testicular size, fertility, and endogenous testosterone production by preventing HPG axis suppression22

  • expert opinionGonadorelin is used to treat reproductive hormone imbalances, infertility, and certain endocrine disorders23

  • expert opinionGonadorelin is used diagnostically to assess pituitary function23

  • expert opinionClinical uses include hormonal replacement therapy for hypogonadism or low sex hormone levels due to pituitary dysfunction23

  • expert opinionThe original branded product Factrel (gonadorelin hydrochloride injection, Wyeth) was withdrawn from the market24

  • expert opinionCompounded gonadorelin is available through licensed compounding pharmacies where permitted24

  • expert opinionOff-label use as a testosterone replacement therapy (TRT) adjunct to preserve testicular volume and spermatogenesis during exogenous testosterone administration lacks published RCT support; evidence is limited to expert opinion and anecdotal clinical reports26

  • expert opinionGnRH was slightly more favoured over HCG among respondents using hormonal therapy for undescended testes27

  • expert opinionAmong those using hormonal therapy for undescended testes, main reason was bilateral UDT (62%)27

  • theoreticalGnRH antagonists are therapeutic for diseases such as advanced prostate cancer, endometriosis, uterine fibroids, and in vitro fertilization procedures10

  • theoreticalThis agent can be used in treatment of hypothalamic amenorrhea and evaluation of hypothalamic/pituitary function11

  • theoreticalFDA-approved for diagnosing hypogonadotropic hypogonadism and evaluating pituitary-gonadal function22

Other findings

Based on 2 expert opinion findings and 1 theoretical finding.

  • expert opinionGonadorelin was available for medical use, under the brand name Factrel, as early as 19783

  • expert opinionD-TRP6-LHRH was synthesized in 1973 by substituting the glycine-6 with a D-tryptophan18

  • theoreticalGonadorelin is a synthetic decapeptide prepared using solid phase peptide synthesis11

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Single source

Reported user benefits (e.g., libido) and dosing come from a single vendor with anecdotal data.

The libido benefit (181 reports), 97% positive community reports from 25 users, side-effect reports, and the 100 mcg 2-3x weekly TRT-adjunct dosing come only from Gonadorelin (GnRH / Factrel) — Dosing, Side Effects, FDA Status & Research | PeptIQ | PeptIQ, a tier-3 vendor page relying on anecdotal community reports rather than controlled studies.

Limited evidence

Key efficacy figures for fertility/CHH use come from retrospective observational studies, not randomized trials.

The high ovulation (96%), pregnancy (74.4%), and live-birth (65.9%) rates and the CHH testosterone/spermatogenesis outcomes are drawn from retrospective cohorts and meta-analyses of observational/comparative studies (Gonadorelin: Mechanism, Dosing & Research — PeptideSciences101, Gonadorelin Peptide Guide: GnRH Evidence and Safety | PeptideStat, Superpower), some reported only via tier-3 web sources, not from randomized controlled trials.

Limited evidence

Anticancer/antiproliferative effects of GnRH are largely preclinical.

Claims that GnRH and its analogs inhibit tumor cell proliferation are mostly in vitro (Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.), theoretical (GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy, Gonadorelin Acetate - an overview, Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer.), or based on receptor-expression observations (Tc-LHRH in tumor receptor imaging.); in the one phase III human trial of a cytotoxic GnRH-doxorubicin conjugate it was not superior to free doxorubicin (The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer.).

Inconsistency

The popular TRT-clinic dose of gonadorelin — roughly 100 mcg injected two or three times a week — does not match how the hormone actually works in the body.

Gonadorelin is cleared very fast, with a terminal half-life of only about 10 to 40 minutes, and the natural hormone has to arrive in pulses roughly every 90 to 120 minutes to keep the pituitary responsive. Continuous, non-pulsatile exposure instead shuts the pituitary receptors down. A dose given only two or three times a week produces a brief rise in LH and FSH that clears within an hour and then leaves days with no signal at all — so it neither reproduces the pulsatile pattern used in fertility therapy nor provides the sustained exposure used to suppress the axis. This weekly-injection regimen comes only from a single vendor's self-reported community data, not from controlled trials, and should not be read as a mechanistically rational maintenance schedule.

Using it with other compounds

Check a stack
  • Kisspeptin-10Same downstream effect

    Worth caution

    Kisspeptin-10 acts one step upstream, telling the hypothalamus's GnRH neurons to release their own GnRH, whereas gonadorelin IS GnRH acting directly on the pituitary. Both funnel into the same output — LH and FSH secretion and the resulting rise in sex steroids. Because they converge on the same HPG endpoint, combining them is largely redundant rather than additive, and both share the receptor desensitization risk if pulsatility isn't preserved.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism descriptions clearly establish that both peptides converge on the same downstream HPG axis endpoint. Gonadorelin directly targets GnRH-R on pituitary gonadotrophs to stimulate LH/FSH secretion and sex steroid increases. Kisspeptin-10 targets KISS1R on hypothalamic GnRH neurons, stimulating GnRH release, which then acts on the same pituitary GnRH-R to produce LH/FSH secretion and testosterone increases. Both are explicitly tagged 'testosterone_axis' and both mechanisms describe the same final output: LH/FSH secretion leading to sex steroid elevation. The explanation correctly identifies kisspeptin-10 as one step upstream (hypothalamic GnRH neuron stimulation) versus gonadorelin's direct pituitary action, yet both converge on identical downstream effects. The redundancy concern and receptor desensitization risk with continuous exposure are also supported by the mechanisms (gonadorelin shows 'receptor downregulation and gonadotropin suppression with continuous exposure'). This is a valid same_downstream relationship.

    Timing If ever used together, maintain pulsatile (not continuous) dosing to avoid gonadotroph desensitization.

    Shares testosterone axis

  • TriptorelinSame mechanism

    Research does not support combining these

    Both gonadorelin and triptorelin act on the very same pituitary GnRH receptor. Gonadorelin is native GnRH given in pulses to stimulate LH/FSH, while triptorelin is a more potent, long-acting GnRH agonist that with continuous exposure downregulates the receptor and shuts the reproductive axis down. Running them together is contradictory: the sustained triptorelin signal would desensitize the same receptor gonadorelin needs, so instead of adding up they work against each other. Choose one strategy (pulsatile stimulation vs. sustained suppression), not both.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides target the same GnRH/LHRH receptor on pituitary gonadotrophs and operate within the testosterone_axis. The mechanism descriptions clearly establish they share the same receptor target and both modulate the HPG axis through this receptor. The explanation correctly identifies that gonadorelin uses pulsatile delivery for stimulation while triptorelin uses continuous delivery for receptor downregulation and suppression—these are indeed opposing strategies on the same mechanism. The proposed relationship of 'same_mechanism' with 'testosterone_axis' as the shared dimension is directly supported by the provided mechanism material.

    Timing Do not co-administer; sustained GnRH-agonist exposure desensitizes the receptor that pulsatile gonadorelin relies on.

    Shares testosterone axis

  • HCGComplementary

    Worth caution

    These act at different levels of the same axis: gonadorelin stimulates the pituitary to make endogenous LH/FSH, while HCG bypasses the pituitary and directly stimulates the gonadal LH receptor to drive testosterone/steroidogenesis. In principle they converge on raising sex steroids by distinct routes. However, HCG's direct gonadal drive and negative feedback can blunt the endogenous pituitary output gonadorelin is trying to restore, so pairing them requires understanding the goal (restoring the natural pituitary signal vs. directly firing the testes) and monitoring.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism descriptions clearly establish that both peptides operate on the testosterone_axis but at different levels: Gonadorelin acts upstream at the pituitary (stimulating LH/FSH release via GnRH-R), while HCG acts downstream at the gonad (directly stimulating LHCGR to drive steroidogenesis). Both ultimately increase sex steroids but through distinct routes—this is the definition of complementary action on a shared axis. The explanation's caveat about negative feedback and monitoring is a clinical consideration that does not contradict the complementary relationship itself. The mechanisms fully support this characterization.

    Shares testosterone axis

Safety and side effects

Safety and Side Effects

Contraindications

Pulsatile therapy (LUTREPULSE) is contraindicated in women with any condition that could be exacerbated by pregnancy (such as pituitary prolactinoma), in patients with ovarian cysts, and in any condition that may be worsened by reproductive hormones such as a hormonally-dependent tumor. Use when a GnRH-secreting adenoma exists may cause pituitary problems and could result in sudden blindness.

Ovulation-Induction Risks

Ovarian hyperstimulation is rare with pulsatile GnRH therapy (fewer than 1% of cases), and severe hyperstimulation with ascites and pleural effusion is rare because endogenous feedback mechanisms are preserved. Multiple pregnancies are possible with ovulation induction but can be minimized by careful attention to recommended doses and ultrasonographic monitoring. Ovarian cancer has been reported in a very small number of infertile women treated with fertility drugs, but a causal relationship has not been established. Pulsatile GnRH delivery therapy should be conducted by physicians familiar with the technique and the clinical ramifications of ovulation induction.

Pediatric Considerations

Safety and efficacy in children under one year have not been established. As a diagnostic test, gonadorelin has been studied only in children 12 years and older, where it has not caused different side effects than in adults; children up to 12 may be less sensitive, while infants may be very sensitive and use in infants is not recommended.

Reported Adverse Effects (anecdotal/vendor sources)

Community and vendor sources report injection-site reactions (redness, bruising, mild pain, irritation), potential allergic reactions (rash or hives), nausea, and headache. These come from a single vendor page relying on anecdotal community reports.

Carcinogenicity

Because GnRH is a natural substance normally present in humans, long-term animal studies to evaluate carcinogenic potential have not been performed.

Hot Flushes

Notably, pulsatile GnRH does not induce hot flushes, whereas continuous administration does — an observation relevant to distinguishing pulsatile therapeutic use from continuous suppressive analogue use.

Reconstitution and handling

Reconstitution and Preparation

Diagnostic Vials

Each diagnostic vial contains 100 micrograms of gonadorelin as the hydrochloride. After reconstitution with 1 mL of water for injections, the vial yields a solution of 100 micrograms/mL.

Formulations

Gonadorelin acetate formulations contain 50 mcg gonadorelin diacetate tetrahydrate per milliliter (equivalent to 43 mcg/mL of gonadorelin) in aqueous solution. Gonadorelin has poor oral bioavailability and is limited to predominantly parenteral routes — it can be given by intravenous injection, subcutaneous injection, or as a nasal spray.

Storage

One vendor recommends that reconstituted gonadorelin solution be refrigerated (2-8°C) and used within 28 days.

Dosing (as reported)

Diagnostic Test

For the GnRH stimulation test, adults and elderly receive a single 100 microgram dose subcutaneously or intravenously. In females for whom the menstrual cycle phase can be established, the test should be performed in the early follicular phase (days 1-7), with seven venous blood samples for LH recommended.

Pulsatile Ovulation Induction

For pulsatile ovulation induction in hypothalamic amenorrhea, the usual dosage is 5 to 20 mcg per pulse delivered subcutaneously every 90 to 120 minutes via a programmable ambulatory infusion pump. Fertility/CHH studies used 10 mcg per 90-minute pulse. A single bolus produces only a transient LH/FSH surge — sustained therapeutic effect requires pulsatile delivery.

Off-Label TRT Adjunct (anecdotal)

One vendor cites a typical off-label dose of 100 mcg subcutaneously 2-3 times weekly (median community dose 100-200 mcg). This dosing derives solely from a single vendor's anecdotal community data and lacks controlled-trial support.

Pharmacokinetic Context

Gonadorelin is cleared primarily by enzymatic hydrolysis into smaller peptide components, with a distribution half-life of about 2-10 minutes and a terminal half-life of roughly 10-40 minutes, underscoring why pulsatile pump delivery (rather than sustained dosing) is required to mimic physiologic secretion.

Sources

Ordered by evidence quality — the strongest first.

  1. Gonadorelin 100 micrograms powder for solution for injection - Summary of Product Characteristics (SmPC) - (emc) | 4853(opens in a new tab)
    Tier 1Web · medicines.org.uk
  2. Gonadorelin (intravenous route, injection route)(opens in a new tab)
    Tier 1Web · mayoclinic.org · 2026
  3. Gonadorelin(opens in a new tab)
    Tier 1Web · en.wikipedia.org · 2025
  4. Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  5. The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  6. Gonadorelin Acetate for Injection(opens in a new tab)
    Tier 1Web · pdf.hres.ca · 2010
  7. GnRH and steroids in cancer.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  8. Induction of ovulation after gnRH antagonists.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2000
  9. The flush revisited.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1994
  10. GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy(opens in a new tab)
    Tier 2Web · mdpi.com
  11. Gonadorelin | C55H75N17O13 | CID 638793 - PubChem(opens in a new tab)
    Tier 2Web · pubchem.ncbi.nlm.nih.gov
  12. Gonadorelin Acetate - an overview(opens in a new tab)
    Tier 2Web · sciencedirect.com
  13. Gonadorelin (GnRH): Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 2Web · peptideinsight.com · 2026
  14. Identification of the FSH-RH as the other gonadotropin-releasing hormone.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  15. Bovine reproductive immunoinfertility: pathogenesis and immunotherapy.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  16. Reproductive performance of goats treated with free gonadorelin or nanoconjugated gonadorelin at estrus.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  17. Tc-LHRH in tumor receptor imaging.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2017
  18. [Pharmacokinetics and pharmacodynamics of triptorelin].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2005
  19. Non-peptidic GnRH receptor antagonists.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2004
  20. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2003
  21. Neuroendocrinology of the pituitary gland.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 1989
  22. Gonadorelin (GnRH / Factrel) — Dosing, Side Effects, FDA Status & Research | PeptIQ | PeptIQ(opens in a new tab)
    Tier 3Web · peptiq.io
  23. Gonadorelin: The Ultimate Guide to Hormonal Regulation and Reproductive Health(opens in a new tab)
    Tier 3Web · youtube.com
  24. Superpower(opens in a new tab)
    Tier 3Web · superpower.com
  25. Gonadorelin Peptide Guide: GnRH Evidence and Safety | PeptideStat(opens in a new tab)
    Tier 3Web · peptidestat.com · 2026
  26. Gonadorelin: Mechanism, Dosing & Research — PeptideSciences101(opens in a new tab)
    Tier 3Web · peptidesciences101.com · 2025
  27. Use of hormonal therapy for undescended testis? Results of a worldwide questionnaire.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  28. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2022